- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/02 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
Patent holdings for IPC class C07D 239/02
Total number of patents in this class: 315
10-year publication summary
|
9
|
9
|
5
|
10
|
1
|
8
|
6
|
2
|
3
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3748 |
18 |
| Novartis AG | 10849 |
11 |
| Boehringer Ingelheim International GmbH | 4650 |
10 |
| Rigel Pharmaceuticals, Inc. | 539 |
9 |
| Janssen Pharmaceutica N.V. | 3392 |
8 |
| Bristol-myers Squibb Company | 4898 |
7 |
| Corteva Agriscience LLC | 2669 |
7 |
| Merck Sharp & Dohme Corp. | 2194 |
6 |
| Abbvie Inc. | 1800 |
6 |
| Vertex Pharmaceuticals Incorporated | 1597 |
5 |
| Hoffmann-La Roche Inc. | 3418 |
4 |
| Takeda Pharmaceutical Company Limited | 2713 |
4 |
| Alexion Pharmaceuticals, Inc. | 635 |
4 |
| Gilead Sciences, Inc. | 2036 |
4 |
| Genentech, Inc. | 3976 |
3 |
| Amgen Inc. | 4074 |
3 |
| DSM IP Assets B.V. | 5591 |
3 |
| Emory University | 1626 |
3 |
| Janssen Sciences Ireland UC | 183 |
3 |
| The Salk Institute for Biological Studies | 445 |
3 |
| Other owners | 194 |